Antidepressant News and Research RSS Feed - Antidepressant News and Research

Antidepressants are medicines that treat depression. Your doctor can prescribe them for you. They can improve your mood, sleep, appetite and concentration. It may take several weeks for them to help. There are several types of antidepressants. You and your doctor may have to try several before finding what works best for you.
St John's Wort may cause same adverse reactions as antidepressants

St John's Wort may cause same adverse reactions as antidepressants

St John's Wort can produce the same adverse reactions as antidepressants, and serious side effects can occur when the two are taken together, according to new University of Adelaide research. [More]
Men referred for borderline testosterone levels have much higher rates of depression than general population

Men referred for borderline testosterone levels have much higher rates of depression than general population

Researchers at the George Washington University, led by Michael S. Irwig, M.D., found that men referred for tertiary care for borderline testosterone levels had much higher rates of depression and depressive symptoms than those of the general population. [More]
Concert Pharmaceuticals’ precision deuteration platform can enhance metabolic properties of drugs

Concert Pharmaceuticals’ precision deuteration platform can enhance metabolic properties of drugs

Substituting deuterium for certain hydrogen atoms in molecules has been shown to enhance the metabolic properties of a number of drugs and provides a promising approach to the discovery and development of innovative drug products. [More]
Study sheds new light on role of patient-doctor relationship in antidepressant drug treatment

Study sheds new light on role of patient-doctor relationship in antidepressant drug treatment

A study published in the current issue of Psychotherapy and Psychosomatic sheds new light on the role of patient-doctor relationship in antidepressant drug treatment. [More]
Person-centered approach to physical therapy has positive effect on depression

Person-centered approach to physical therapy has positive effect on depression

Exercise has a positive effect on depression - so reveals a dissertation written at the Sahlgrenska Academy. In at study at the Sahlgrenska Academy, the researcher evaluated exercise as add-on therapy to medicating with antidepressants. The study divided 62 individuals with diagnosed clinical depression into three groups, in which two participated in two different types of exercise with a physiotherapist twice a week for 10 weeks while the third, the control group, did not participate in systematic exercise. [More]
Recurrent major depression may increase osteoporosis risk in men

Recurrent major depression may increase osteoporosis risk in men

A recent study from the University of Eastern Finland in collaboration with Deakin University, Australia, shows that recurrent major depressive disorder (MDD) in men is associated with lower bone density. The use of antidepressants was also associated with lower bone mineral density (BMD), but this association was dependent on the person's weight and site of bone measurement. [More]
Use of antidepressants in late pregnancy may be associated with increased risk of PPHN

Use of antidepressants in late pregnancy may be associated with increased risk of PPHN

An analysis of approximately 3.8 million pregnancies finds that use of antidepressants late in pregnancy may be associated with an increased risk of persistent pulmonary hypertension of the newborn (PPHN), according to a study in the June 2 issue of JAMA. However, the absolute risk was small and the risk increase appears more modest than suggested in previous studies. [More]
Researchers explore association between SSRI exposure in late pregnancy and risk of PPHN

Researchers explore association between SSRI exposure in late pregnancy and risk of PPHN

Use of antidepressants late in pregnancy has been controversial since the FDA issued a Public Health Advisory in 2006 warning that the use of antidepressants in late pregnancy may increase risk of persistent pulmonary hypertension of the newborn (PPHN), a condition that typically occurs in term or near-term infants and presents within hours of birth with severe respiratory failure requiring intubation and mechanical ventilation. [More]

Study explores efficacy of selective serotonin reuptake inhibitors in reducing depressed mood

Many have recently questioned the efficacy of the most common antidepressant medications, the selective serotonin reuptake inhibitors (SSRIs). The conclusion that these drugs are ineffective is however partly based on a misinterpretation of the outcome of the clinical trials once conducted to demonstrate their efficacy. This was the finding of a study conducted by researchers at the Sahlgrenska Academy. [More]
Researchers design new model to identify promising candidates for total hip replacement surgery

Researchers design new model to identify promising candidates for total hip replacement surgery

Researchers at Sahlgrenska Academy have designed a new model to help doctors and patients decide whether or not to proceed with total hip replacement surgery. The researchers have also surveyed patient wellbeing after surgery: patients with high education achieve greater outcome scores, while those with antidepressant prescriptions do not. [More]
Manic symptoms during depression warn of polarity switch

Manic symptoms during depression warn of polarity switch

Concomitant manic symptoms and panic attacks are the strongest predictors of an impending switch to mania among patients with bipolar disorder who are currently depressed, shows analysis of the STEP-BD study. [More]
Aptensio XR once-daily treatment for ADHD to be available in Summer 2015

Aptensio XR once-daily treatment for ADHD to be available in Summer 2015

Today, Rhodes Pharmaceuticals L.P. announced that Aptensio XR, a once-daily central nervous system stimulant indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) will be available to patients beginning Summer 2015. [More]
Magstim Rapid2 Therapy System receives FDA clearance for treatment of drug resistant MDD

Magstim Rapid2 Therapy System receives FDA clearance for treatment of drug resistant MDD

The Magstim Company Ltd, an innovative and award winning Wales-based medical device manufacturer, has received FDA 510(k) clearance to market its Magstim Rapid2 Therapy System for the treatment of drug resistant Major Depressive Disorder (MDD) in the United States. The clearance enables Magstim to significantly increase access to cutting-edge Repetitive Transcranial Magnetic Stimulation (rTMS) technology for patients and clinicians. [More]
New method may help determine potential indicator of stress, neurological disorders

New method may help determine potential indicator of stress, neurological disorders

A research collaboration between the universities of Oslo and Aarhus has resulted in the development of a new method with diagnostic potential. The new method that combines phase extraction with an enzymatic reaction may eventually be used for an improved and faster screening analysis of isatin as a potential indicator of stress and neurological disorders. [More]
Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics, Inc. today announced business and financial results for the first quarter ended March 31, 2015. [More]
MSI completes patient recruitment for STRADA Phase 2 trial for treatment of major depressive disorder

MSI completes patient recruitment for STRADA Phase 2 trial for treatment of major depressive disorder

MSI Methylation Sciences, Inc., a pharmaceutical company developing a once-daily oral, small molecule therapy for adjunctive treatment of major depressive disorder (MDD), announced the completion of patient recruitment for its HORIZON Phase 2 Study. [More]
Clinical features identified to distinguish bipolar I disorder from MDD

Clinical features identified to distinguish bipolar I disorder from MDD

Researchers have identified seven clinical features that could help distinguish patients with bipolar disorder from those with major depressive disorder. [More]
Neuronetics completes Series F Financing Round

Neuronetics completes Series F Financing Round

Neuronetics, Inc., the established market leader in transcranial magnetic stimulation (TMS) technology, announced today the completion of its Series F Financing Round, which included investment from GE Ventures, as well as its original investor base totaling $34.3 million. [More]

Mindfulness-based cognitive therapy could offer new treatment choice for people with recurrent depression

Mindfulness-based cognitive therapy (MBCT) could provide an alternative non-drug treatment for people who do not wish to continue long-term antidepressant treatment, suggests new research published in The Lancet. [More]
Tal Medical raises $14 million funding round from new and existing investors

Tal Medical raises $14 million funding round from new and existing investors

Tal Medical, a clinical-stage medical device company developing a new treatment for depression and other psychiatric disorders, today announced a $14 million funding round from existing investor PureTech, a new institutional investor, and several prominent individual investors. [More]
Advertisement
Advertisement